AN1004 (Pelareorep)

AN1004 is a non-pathogenic, proprietary isolate of the unmodified reovirus. A first-in-class intravenously delivered immuno-oncolytic virus (IOV) for the treatment of solid tumors and hematological malignancies. It induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Actively turning 'COLD' tumors 'HOT'.


We have received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for AN1004 in combination with paclitaxel in patients with advanced/metastatic breast cancer in China.


 Mechanism of Action
Latest progress
We have received a clearance from the NMPA of China for initiating the phase III clinical trial. Now the phase I trial for (AN1004 in combination with paclitaxel in patients with advanced/metastatic breast cancer in China is on going.
About Breast Cancer

Breast cancer is the most common cancer in women worldwide, with over two million new cases diagnosed in 2018, representing about 25 percent of all cancers in women. Incidence rates vary widely across the world, from 27 per 100,000 in Middle Africa and Eastern Asia to 85 per 100,000 in Northern America. It is the fifth most common cause of death from cancer in women globally, with an estimated 522,000 deaths.